FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Lynn Schuchter

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Occupations

Medical Oncology

Co-author Network

Publications

TOP 3
Kerstin Trunzer; Jeffrey S Weber; Annette Schell-Steven; Lynn Schuchter; Jeffrey A Sosman; Olivia Spleiss; Ravi K Amaravadi; Gideon Bollag; Louise Cockey; Keith T Flaherty; Houston N Gilbert; Rene Gonzalez; Peter Hersey; Thomas E Hutson; Andrew K Joe; Kevin B Kim; Mark Kockx; Astrid Koehler; Donald Lawrence; Richard J Lee; Karl D Lewis; Roger S Lo; Georgina V Long; Grant A McArthur; Stergios J Moschos; Patrick A Ott; Anna C Pavlick; Igor Puzanov; Antoni Ribas
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Emily Y Chu; Leslie A Fecher; Lydia R Giles; Suzanne McGettigan; Christopher J Miller; Ravi K Amaravadi; Marcia S Brose; Lynn Schuchter; John T Seykora; Karolyn A Wanat; Misha Rosenbach
Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
Jeffrey A Sosman; Jeffrey S Weber; Fei Ye; Lynn Schuchter; Yu Shyr; Ravi K Amaravadi; Bartosz Chmielowski; Keith T Flaherty; Rene Gonzalez; Peter Hersey; Thomas E Hutson; Andrew K Joe; Richard Kefford; Kevin B Kim; Donald Lawrence; H Jeffrey Lawrence; Richard J Lee; Karl D Lewis; Jiang Li; Grant A McArthur; Stergios J Moschos; Keith B Nolop; Anna C Pavlick; Igor Puzanov; Antoni Ribas
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Lynn Schuchter (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Kerstin Trunzer; Jeffrey S Weber; Annette Schell-Steven; Lynn Schuchter; Jeffrey A Sosman; Olivia Spleiss; Ravi K Amaravadi; Gideon Bollag; Louise Cockey; Keith T Flaherty; Houston N Gilbert; Rene Gonzalez; Peter Hersey; Thomas E Hutson; Andrew K Joe; Kevin B Kim; Mark Kockx; Astrid Koehler; Donald Lawrence; Richard J Lee; Karl D Lewis; Roger S Lo; Georgina V Long; Grant A McArthur; Stergios J Moschos; Patrick A Ott; Anna C Pavlick; Igor Puzanov; Antoni Ribas
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(14):1767-74.
2012: Emily Y Chu; Leslie A Fecher; Lydia R Giles; Suzanne McGettigan; Christopher J Miller; Ravi K Amaravadi; Marcia S Brose; Lynn Schuchter; John T Seykora; Karolyn A Wanat; Misha Rosenbach
Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
Journal of the American Academy of Dermatology 2012;67(6):1265-72.
2012: Jeffrey A Sosman; Jeffrey S Weber; Fei Ye; Lynn Schuchter; Yu Shyr; Ravi K Amaravadi; Bartosz Chmielowski; Keith T Flaherty; Rene Gonzalez; Peter Hersey; Thomas E Hutson; Andrew K Joe; Richard Kefford; Kevin B Kim; Donald Lawrence; H Jeffrey Lawrence; Richard J Lee; Karl D Lewis; Jiang Li; Grant A McArthur; Stergios J Moschos; Keith B Nolop; Anna C Pavlick; Igor Puzanov; Antoni Ribas
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
The New England journal of medicine 2012;366(8):707-14.
2011: Keith T Flaherty; Reginald F Frye; Chetan Lathia; Maryann Redlinger; Mark Rosen; Lynn Schuchter; Peter J O'Dwyer
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Cancer chemotherapy and pharmacology 2011;68(5):1111-8.
2011: Hongtao Zhang; Ting Fu; Suresh Kumar; Shujing Liu; Suzanne McGettigan; Lynn Schuchter; David Speicher; Xiaowei Xu
IL8 and Cathepsin B as Melanoma Serum Biomarkers.
International journal of molecular sciences 2011;12(3):1505-18.
2010: Peter Kanetsky; Saarene Panossian; David E Elder; DuPont Guerry; Michael E Ming; Lynn Schuchter; Timothy R Rebbeck
Does MC1R genotype convey information about melanoma risk beyond risk phenotypes?
Cancer 2010;116(10):2416-28.
2009: Nicholas J Petrelli; Eric P Winer; Julie R Brahmer; Sarita Dubey; Sonali Smith; Charles Thomas; Linda Vahdat; Jennifer Obel; Nicholas Vogelzang; Maurie Markman; John W Sweetenham; David G Pfister; Mark G Kris; Lynn Schuchter; Raymond Sawaya; Derek Raghavan; Patricia Anne Ganz; Barnett Kramer
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(35):6052-69.
2009: Erica L Carpenter; Rosemarie Mick; Andrew J Rech; Gregory L Beatty; Theresa A Colligon; Myrna R Rosenfeld; David Edward Kaplan; Kyong-Mi Chang; Susan M Domchek; Peter Kanetsky; Leslie A Fecher; Keith T Flaherty; Lynn Schuchter; Robert H Vonderheide
Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(13):4277-87.
2009: Leslie A Fecher; Ravi K Amaravadi; Lynn Schuchter; Keith T Flaherty
Drug targeting of oncogenic pathways in melanoma.
Hematology/oncology clinics of North America 2009;23(3):599-618, x.
2008: Keith T Flaherty; Joan Schiller; Lynn Schuchter; Glenn Liu; David A Tuveson; Maryann Redlinger; Chetan Lathia; Chenghua Xia; Oana Petrenciuc; Sunil R Hingorani; Michael Jacobetz; Patricia Van Belle; David E Elder; Marcia S Brose; Barbara L Weber; Mark R Albertini; Peter J O'Dwyer
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(15):4836-42.
2008: Julie R Gralow; Robert F Ozols; Dean F Bajorin; Bruce D Cheson; Howard M Sandler; Eric P Winer; James Bonner; George D Demetri; Walter Curran; Patricia Anne Ganz; Barnett S Kramer; Mark G Kris; Maurie Markman; Robert J Mayer; Derek Raghavan; Scott Ramsey; Gregory H Reaman; Raymond Sawaya; Lynn Schuchter; John W Sweetenham; Linda Vahdat; Nancy E Davidson; Richard L Schilsky; Allen S Lichter
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):313-25.
2007: Meenhard Herlyn; Ruth Halaban; Ze'ev Ronai; Lynn Schuchter; Marianne Berwick; Daniel Pinkel
Roadmap for new opportunities in melanoma research.
Seminars in oncology 2007;34(6):566-76.
2007: Susan M Domchek; Adri Recio; Rosemarie Mick; Carolyn E Clark; Erica L Carpenter; Kevin R Fox; Angela DeMichele; Lynn Schuchter; Michael S Leibowitz; Michael H Wexler; Barbara A Vance; Gregory L Beatty; Elizabeth Veloso; Michael D Feldman; Robert H Vonderheide
Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance.
Cancer research 2007;67(21):10546-55.
2007: Rolf Swoboda; Rajasekharan Somasundaram; Laura Caputo; Elizabeth M Ochoa; Phyllis A Gimotty; Francesco M Marincola; Patricia Van Belle; Stephen Barth; David E Elder; DuPont Guerry; Brian J Czerniecki; Lynn Schuchter; Robert H Vonderheide; Dorothee Herlyn
Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display.
Cancer research 2007;67(8):3555-9.
2007: Phyllis A Gimotty; David E Elder; Douglas L Fraker; Jeffrey Botbyl; Kimberly Sellers; Rosalie Elenitsas; Michael E Ming; Lynn Schuchter; Francis R Spitz; Brian J Czerniecki; DuPont Guerry
Identification of high-risk patients among those diagnosed with thin cutaneous melanomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(9):1129-34.
2007: Robert F Ozols; Roy S Herbst; Yolonda L Colson; Julie R Gralow; James Bonner; Walter Curran; Burton L Eisenberg; Patricia Anne Ganz; Barnett S Kramer; Mark G Kris; Maurie Markman; Robert J Mayer; Derek Raghavan; Gregory H Reaman; Raymond Sawaya; Richard L Schilsky; Lynn Schuchter; John W Sweetenham; Linda Vahdat; Rodger J Winn
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):146-62.
2006: Tianqian Zhang; Rajasekharan Somasundaram; Carola Berking; Laura Caputo; Patricia Van Belle; David E Elder; Brian J Czerniecki; Susan Hotz; Lynn Schuchter; Francis R Spitz; Klara Berencsi; Pyapalli Rani; Francesco M Marincola; Ruihua Qiu; Dorothee Herlyn
Preferential involvement of CX chemokine receptor 4 and CX chemokine ligand 12 in T-cell migration toward melanoma cells.
Cancer biology & therapy 2006;5(10):1304-12.
2006: Rajasekharan Somasundaram; Rolf Swoboda; Laura Caputo; Laszlo Otvos; Barbara Weber; Patricia Volpe; Patricia Van Belle; Susan Hotz; David E Elder; Francesco M Marincola; Lynn Schuchter; DuPont Guerry; Brian J Czerniecki; Dorothee Herlyn
Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients.
Cancer research 2006;66(6):3287-93.
2006: Benjamin M Jackson; Samuel Kim; Rebecca Davidson; Lynn Schuchter; Geza Acs; Brian J Czerniecki
Repeat operative sentinel lymph node biopsy.
Clinical breast cancer 2006;6(6):530-2.
2006: Roy S Herbst; Dean F Bajorin; Harry Bleiberg; Diane Blum; Desirée Hao; Bruce E Johnson; Robert F Ozols; George D Demetri; Patricia Anne Ganz; Mark G Kris; Bernard Levin; Maurie Markman; Derek Raghavan; Gregory H Reaman; Raymond Sawaya; Lynn Schuchter; John W Sweetenham; Linda Vahdat; Everett E Vokes; Rodger J Winn; Robert J Mayer
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):190-205.
2005: Karen Smith; Lisa Wray; Melissa Klein-Cabral; Lynn Schuchter; Kevin Fox; John Glick; Angela DeMichele
Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patients.
Clinical breast cancer 2005;6(3):260-6; discussion 267-9.
2004: Phyllis A Gimotty; DuPont Guerry; Michael E Ming; Rosalie Elenitsas; Xiaowei Xu; Brian J Czerniecki; Francis R Spitz; Lynn Schuchter; David E Elder
Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(18):3668-76.
2004: David Fuster; Stephen Chiang; Germaine Johnson; Lynn Schuchter; Hongming Zhuang; Abass Alavi
Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma?
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2004;45(8):1323-7.
2004: Peter Kanetsky; Fan Ge; Derek Najarian; Jennifer Swoyer; Saarene Panossian; Lynn Schuchter; Robin Holmes; DuPont Guerry; Timothy R Rebbeck
Assessment of polymorphic variants in the melanocortin-1 receptor gene with cutaneous pigmentation using an evolutionary approach.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2004;13(5):808-19.
2004: Lynn Schuchter
Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(1):7-10.
2003: Wendy G Lichtenthal; Dean G Cruess; Lynn Schuchter; Michael E Ming
Psychosocial factors related to the correspondence of recipient and provider perceptions of social support among patients diagnosed with or at risk for malignant melanoma.
Journal of health psychology 2003;8(6):705-19.
2003: Lynn Schuchter; Neal J Meropol; Eric P Winer; Martee Hensley; Mark R Somerfield
Amifostine and chemoradiation therapy: ASCO responds.
The lancet oncology 2003;4(10):593.
2003: Alison W Loren; Shashank Desai; Robert Gorman; Lynn Schuchter
Retransplantation of a cardiac allograft inadvertently harvested from a donor with metastatic melanoma.
Transplantation 2003;76(4):741-3.
2003: Genevieve Hollis; Adri Recio; Lynn Schuchter
Diagnosis and management of high-risk and metastatic melanoma.
Seminars in oncology nursing 2003;19(1):32-42.
2002: Timothy D Anderson; Randal S Weber; DuPont Guerry; David E Elder; Lynn Schuchter; Laurie A Loevner; David I Rosenthal
Desmoplastic neurotropic melanoma of the head and neck: the role of radiation therapy.
Head & neck 2002;24(12):1068-71.
2002: James P Stevenson; Weijing Sun; Maryann Gallagher; Robert Johnson; David Vaughn; Lynn Schuchter; Kenneth M Algazy; Stephen Hahn; Nathan Enas; Diane Ellis; Donald Thornton; Peter J O'Dwyer
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(8):2524-9.
2002: Timothy R Rebbeck; Peter Kanetsky; Amy H Walker; Robin Holmes; Allan C Halpern; Lynn Schuchter; David E Elder; DuPont Guerry
P gene as an inherited biomarker of human eye color.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2002;11(8):782-4.
2002: Lynn Schuchter; Martee Hensley; Neal J Meropol; Eric P Winer
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(12):2895-903.
2002: Karen S McGinnis; Stuart R Lessin; David E Elder; DuPont Guerry; Lynn Schuchter; Michael E Ming; Rosalie Elenitsas
Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic.
Archives of dermatology 2002;138(5):617-21.
2002: M Anne Blackwood; Robin Holmes; Marie Synnestvedt; Megan Young; Cicily George; Hannah Yang; David E Elder; Lynn Schuchter; DuPont Guerry; Arupa Ganguly
Multiple primary melanoma revisited.
Cancer 2002;94(8):2248-55.
2002: Evan Alley; Robert Green; Lynn Schuchter
Cutaneous toxicities of cancer therapy.
Current opinion in oncology 2002;14(2):212-6.
2001: John K Wildemore; Lynn Schuchter; Rosemarie Mick; Marie Synnestvedt; Rosalie Elenitsas; Isabelle Bedrosian; Brian J Czerniecki; DuPont Guerry; Stuart R Lessin; David E Elder; Louis P Bucky
Locally recurrent malignant melanoma characteristics and outcomes: a single-institution study.
Annals of plastic surgery 2001;46(5):488-94.
2001: J H Chang; E Vines; Helaine Bertsch; Douglas L Fraker; Brian J Czerniecki; Ernest F Rosato; Thomas Lawton; Emily F Conant; Susan G Orel; Lynn Schuchter; Kevin R Fox; N Zieber; John Glick; Lawrence J Solin
The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience.
Cancer 2001;91(7):1231-7.
2000: Isabelle Bedrosian; Mark Faries; DuPont Guerry; Rosalie Elenitsas; Lynn Schuchter; Rosemarie Mick; Francis R Spitz; Louis P Bucky; Abass Alavi; David E Elder; Douglas L Fraker; Brian J Czerniecki
Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase.
Annals of surgical oncology 2000;7(4):262-7.
2000: S Visonneau; A Cesano; David Porter; S L Luger; Lynn Schuchter; M Kamoun; MH Torosian; K Duffy; CJ Sickles; Edward A Stadtmauer; Daniela Santoli
Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1744-54.
2000: Lynn Schuchter; R Green; Douglas L Fraker
Primary and metastatic diseases in malignant melanoma of the gastrointestinal tract.
Current opinion in oncology 2000;12(2):181-5.
1999: Edward A Stadtmauer; Donald E Tsai; CJ Sickles; Rosemarie Mick; Selina M Luger; David Porter; Patricia A Mangan; Lynn Schuchter; Stephen J Schuster; E Y Loh; D A Magee; R A Sachs; M E Wall; J Moore; Gordon P Buzby; E Zaleta; M Kamoun; Leslie E Silberstein
Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination.
Medical oncology (Northwood, London, England) 1999;16(4):279-88.
1999: Martee Hensley; Lynn Schuchter; Celeste Lindley; N J Meropol; GARY COHEN; G Broder; W J Gradishar; D M Green; R J Langdon; R B Mitchell; R Negrin; Ted P Szatrowski; J T Thigpen; Daniel Von Hoff; T H Wasserman; Eric P Winer; David G Pfister
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3333-55.
1999: HC Moore; Rosemarie Mick; L J Solin; CJ Sickles; Patricia A Mangan; Selina M Luger; K R Fox; Lynn Schuchter; E Loh; David Porter; S Schuster; Gordon P Buzby; Eli Glatstein; Leslie E Silberstein; Edward A Stadtmauer
Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(8):929-36.
1999: Susan G Orel; Susan P Weinstein; Mitchell D Schnall; CA Reynolds; Lynn Schuchter; Douglas L Fraker; Lawrence J Solin
Breast MR imaging in patients with axillary node metastases and unknown primary malignancy.
Radiology 1999;212(2):543-9.
1999: Leslie M Shaw; Heather S Bonner; Lynn Schuchter; J Schiller; R Lieberman
Pharmacokinetics of amifostine: effects of dose and method of administration.
Seminars in oncology 1999;26(2 Suppl 7):34-6.
1999: S Sabir; William D James; Lynn Schuchter
Cutaneous manifestations of cancer.
Current opinion in oncology 1999;11(2):139-44.
1998: David J Margolis; Allan C Halpern; T Rebbeck; Lynn Schuchter; R L Barnhill; J Fine; M Berwick
Validation of a melanoma prognostic model.
Archives of dermatology 1998;134(12):1597-601.
1998: R J Green; Lynn Schuchter
Systemic treatment of metastatic melanoma with chemotherapy.
Hematology/oncology clinics of North America 1998;12(4):863-75, viii.
1998: R Elenitsas; Lynn Schuchter
The role of the pathologist in the diagnosis of melanoma.
Current opinion in oncology 1998;10(2):162-9.
1997: Kevin K Anbari; Lynn Schuchter; Louis P Bucky; Rosemarie Mick; Marie Synnestvedt; DuPont Guerry; R Hamilton; Allan C Halpern
Melanoma of unknown primary site: presentation, treatment, and prognosis--a single institution study. University of Pennsylvania Pigmented Lesion Study Group.
Cancer 1997;79(9):1816-21.
1997: Lynn Schuchter
Current role of protective agents in cancer treatment.
Oncology (Williston Park, N.Y.) 1997;11(4):505-12, 515-6; discussion 517-8.
1997: Allan C Halpern; Lynn Schuchter
Prognostic models in melanoma.
Seminars in oncology 1997;24(1 Suppl 4):S2-7.
1996: Lynn Schuchter; D J Schultz; Marie Synnestvedt; Bruce J Trock; DuPont Guerry; David E Elder; Rosalie Elenitsas; W H Clark; Allan C Halpern
A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group.
Annals of internal medicine 1996;125(5):369-75.
1996: Lynn Schuchter
Guidelines for the administration of amifostine.
Seminars in oncology 1996;23(4 Suppl 8):40-3.
1996: Lynn Schuchter
Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol).
European journal of cancer (Oxford, England : 1990) 1996;32A Suppl 4():S40-2.
1994: Allan C Halpern; Lynn Schuchter; David E Elder; DuPont Guerry; Rosalie Elenitsas; Bruce J Trock; I Matozzo
Effects of topical tretinoin on dysplastic nevi.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(5):1028-35.
1992: Lynn Schuchter; W E Luginbuhl; N J Meropol
The current status of toxicity protectants in cancer therapy.
Seminars in oncology 1992;19(6):742-51.
1992: Lynn Schuchter; J Wohlganger; elliot fishman; M L MacDermott; W P McGuire
Sequential chemotherapy and immunotherapy for the treatment of metastatic melanoma.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(4):272-6.
1992: DuPont Guerry; Lynn Schuchter
Disseminated melanoma--is there a new standard therapy?
The New England journal of medicine 1992;327(8):560-1.
1992: N J Meropol; L L Miller; E L Korn; L E Braitman; M L MacDermott; Lynn Schuchter
Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy.
Journal of the National Cancer Institute 1992;84(15):1201-3.
1992: H P Redmond; Lynn Schuchter; D Bartlett; Carolyn J Kelly; J Shou; P Leon; John M Daly
Anti-neoplastic effects of interleukin-4.
The Journal of surgical research 1992;52(4):406-11.
1990: Lynn Schuchter; C B Hendricks; K H Holland; B K Shelton; Grover M Hutchins; K L Baughman; David S Ettinger
Eosinophilic myocarditis associated with high-dose interleukin-2 therapy.
The American journal of medicine 1990;88(4):439-40.